AMCo (Amdipharm Mercury group) today announces the acquisition of Focus Pharmaceuticals Limited ("Focus"), a speciality pharma business in the UK. The acquisition is being made via AMCo's subsidiary Mercury Pharma Group Ltd.
Focus was founded in Burton on Trent in 2003 and sells branded and generic niche medicines. It has successfully grown revenues to just under £40m. These sales are predominantly in the UK, although the company has developed a number of products that can be registered and sold throughout Europe.
The acquisition of Focus is in keeping with AMCo's strategy of identifying niche medicines and opportunities to expand its sales base throughout AMCo's growing international platform. AMCo currently sells its products in over 100 countries worldwide.
John Beighton, Chief Executive of AMCo, commented: "I have been impressed by the team at Focus, who have created an exciting company and a portfolio of niche medicines which are highly complementary to those of AMCo. I look forward to building on this success by introducing the Focus portfolio into AMCo's international sales network, thereby releasing its wider potential."
Mark Cresswell, Focus CEO commented: "This combination with AMCo will enable many of the products developed over the last 10 years to be taken internationally faster and more efficiently than Focus could have taken them. This is an exciting time for the two businesses, which will be stronger and more vibrant going forward as a result. "